ClinicalTrials.gg
CompletedNCT00411190Updated Oct 4, 2017

Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin

A Phase 1 interventional study of Relacatib and Acetaminophen in Osteoarthritis, sponsored by GlaxoSmithKline. Completed at 2 sites in Belgium. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-04.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing acetaminophen in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis.

Enrollment
9th of 14
32 · median 79
Started
2006
the only one that year
Phase 1
Only one
of the 14
Registered
4th of 14
by date
Lead sponsor
2 of 14
GlaxoSmithKline

Among the 14 studies testing acetaminophen in Osteoarthritis, this one is the 9th largest by enrollment, is the only one that started in 2006, is the only one in phase 1, and was the 4th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 14 studies testing acetaminophen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing acetaminophen in Osteoarthritis as a file.
02

Study summary

Relacatib is being developed for the treatment of osteoporosis, osteoarthritis and possibly other bone disorders. Recent results suggest that relacatib interacts with the way our bodies metabolise drugs and so some drugs which are commonly prescribed to the intended target patient population could be affected by giving relacatib at the same time. The purpose of this study is to evaluate the effect of repeat dose administration of relacatib on the way subjects bodies metabolise three commonly prescribed medications in the osteoarthritis population: ibuprofen, acetaminophen, and atorvastatin.

03

Conditions studied

  • Osteoarthritis

Keywords

  • Osteoarthritis
  • Postmenopausal
  • Osteoporosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy
  • Body weight > 50 kg
  • (BMI) between 19 and 30
  • The subject is willing and able to give a signed and dated written prior to admission to the study
  • The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known morphea or sclerodermia
  • Subjects with a history of myocardial infarction.
  • Subjects with a history of renal/or hepatic disease unless the disease has been successfully treated and is no longer active; subjects with any evidence of renal/ or hepatic impairment on the screening physical and laboratory examination.
  • Subjects with history of hypertension or systolic blood pressure
  • Subjects with history of diabetes
  • History of regular alcohol consumption exceeding 7 drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.
  • History of use of tobacco- or nicotine-containing products within 6 months of screening, or a positive urine cotinine indicative of smoking at screening.
  • Positive urine drug screen including alcohol (or alcohol breath test) at screening.
  • Positive for , virus or virus.
  • Donation of blood in excess of 500 mL within 56 days prior to dosing
  • History of sensitivity or to any of the study medications (i.e., relacatib, paracetamol, ibuprofen or atorvastatin) or components thereof.
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Subjects whom are judged by the investigator to be at risk for acute angle closure glaucoma.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Session 1

    Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.

    Drug: Acetaminophen · Drug: Ibuprofen · Drug: Atorvastatin

  • Experimental
    Session 2

    Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.

    Drug: Relacatib · Drug: Acetaminophen · Drug: Ibuprofen · Drug: Atorvastatin

Interventions

  • DrugRelacatib

    Subjects will administer 60 or 120 mg tablets in Session 2

  • Acetaminophen will be administered orally

  • Ibuprofen will be administered orally

  • Atorvastatin will be administered orally

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to characterize the effect of relacatib at steady-state on the pharmacokinetics of a single oral dose of acetaminophen, ibuprofen and atorvastatin in healthy postmenopausal females.

    Time frame: Up to Day 17

Secondary outcomes

  1. To assess the safety and tolerability of the concomitant administration of oral doses of relacatib and acetaminophen, ibuprofen and atorvastatin. To describe the changes from baseline in serum CTXI levels for each relacatib dose tested.

    Time frame: Up to Day 17

07

Study locations

2 sites
  • GSK Investigational Site
    Antwerpen, 2060, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2006 to primary completion in Dec 2006, 1 month.

Of 35 industry-sponsored phase 1 interventional studies under Osteoarthritis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 1 month is below that.

Counting every sponsor, half of 58 studies reached it within 20 months; a quarter within 9 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2006
First posted
Dec 13, 2006
StartActual
Oct 19, 2006
Primary completionActual
Dec 15, 2006
CompletionActual
Dec 15, 2006
Last update
Oct 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00411190
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 13, 2006
Start date
Oct 19, 2006
Primary completion
Dec 15, 2006
Completion
Dec 15, 2006
Last update
Oct 4, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Ibuprofen · Atorvastatin

Start the discussion